Journal article

Systematic review of incretin therapy during peri-operative and intensive care

Abraham H Hulst, Mark P Plummer, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Adam M Deane, Jeroen Hermanides

Critical Care (UK) | BMC | Published : 2018


BACKGROUND: Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones. By lowering blood glucose in a glucose-dependent manner, incretin-based therapies represent a novel and promising intervention to treat hyperglycaemia in hospital settings. We performed a systematic review of the literature for all current applications of incretin-based therapies in the peri-operative and critical care settings. METHODS: We searched MEDLINE, the Cochrane Library, and Embase databases for all randomised controlled trials using exogenous GLP-1, GLP-1 receptor agonists, exogenous GIP and dipeptidyl peptidase IV inhibitors in the setting of adult peri-operative c..

View full abstract